The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion
Open accessAbstract
Objective: An expert panel convened to reach a consensus on common misconceptions surrounding buprenorphine, a Schedule III partial µ-opioid receptor agonist indicated for chronic pain. The panel also provided clinical recommendations on the appropriate use of buprenorphine and conversion strategies for switching to buprenorphine from a full µ-opioid receptor agonist for chronic pain management. Methods: The consensus panel met on March 25, 2019, to discuss relevant literature and provide recommendations on interpreting buprenorphine as a partial µ-opioid receptor agonist, prescribing buprenorphine before some Schedule II, III, or IV options, perioperative/trauma management of patients taking buprenorphine, and converting patients from a full µ-opioid receptor agonist to buprenorphine. Results: The panel recommended that buprenorphine’s classification as a partial µ-opioid receptor agonist not be clinically translated to mean partial analgesic efficacy. The panel also recommended that buprenorphine be considered before some Schedule II, III, or IV opioids in patients with a favorable risk/benefit profile on the basis of metabolic factors, abuse potential, and tolerability and that buprenorphine be continued during the perioperative/trauma period. In addition, switching patients from a full µ-opioid receptor agonist to buprenorphine should be considered with no weaning period at starting doses that are based on the previous opioid dose. Conclusions: These recommendations provide a framework for clinicians to address most clinical scenarios regarding buprenorphine use. The overall consensus of the panel was that buprenorphine is a unique Schedule III opioid with favorable pharmacologic properties and a safety profile that may be desirable for chronic pain management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The history of buprenorphine. Buprenorphine was originally developed as an analgesic and was subsequently used for OUD before novel delivery systems allowed for approval in chronic pain management [8,9,12,13]. FDA=Food and Drug Administration; OUD=opioid use disorder.](/paper-figures/58cc0d7e0c974ec28f2b0cc30c34f79a/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-1.jpg)
![Figure 2 Receptor/ligand definitions and applications to buprenorphine at the μ-opioid receptor. *Definition of a partial agonist: a compound with an intermediate intrinsic activity that at full receptor saturation produces less than the maximal effect obtainable with full agonists in some specified set of in vitro or clinical circumstances [25]. Buprenorphine is a potent Schedule III opioid with high binding affinity at the μ-opioid receptor that behaves as a partial agonist on the basis of in vitro studies [7,14,26]. Although buprenorphine has less total intrinsic activity (capacity to activate a receptor to induce multiple signaling pathways) than full μ-opioid receptor agonists, it still effectively stimulates the analgesic signaling pathway from the μ-opioid receptor [7,14,25,27,28]. 3D=three-dimensional; OR=opioid receptor.](/paper-figures/70555884c62b4bf48113c2321c3df2a7/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-2.jpg)
![Figure 3 Efficacy and tolerability of buprenorphine compared with those of other opioids used for chronic pain. (A) Potential mechanism of action for buprenorphine and (B) conceptual representation of possible effects compared with those of Schedule II opioids such as, but not limited to, fentanyl [33,38,39]. OR=opioid receptor; ORL1=opioid receptor-like 1.](/paper-figures/fe01b988dfd948c9948091ab1e0785a9/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016
Dahlhamer, J., Lucas, J., Zelaya, Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., & Helmick, C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6736a2 · Cited by 2,598
Consensus development methods, and their use in clinical guideline development.
Murphy, Black, Lamping, McKee, Sanderson, Askham, & Marteau (1998) · Health Technology Assessment · doi:10.3310/hta2030 · Cited by 2,051
Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies
Volkow, N. D., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1507771 · Cited by 1,305
Webster, L. R., & Webster, R. M. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00072.x · Cited by 1,096
Self-citationA review of chronic pain impact on patients, their social environment and the health care system
Duenas, M., Ojeda, B., Salazar, A., Mico, J. A., & Failde, I. (2016) · Journal of Pain Research · doi:10.2147/jpr.s105892 · Cited by 985
Consensus development methods, and their use in clinical guideline development.
Murphy, M. P., Black, N. A., Lamping, D. L., et al. (1998) · PubMed · Cited by 965
Opioids and the control of respiration
Pattinson, K. T. S. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aen094 · Cited by 793
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Opioids and the treatment of chronic pain: Controversies, current status, and future directions.
Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013628 · Cited by 643
AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Research works printed but not linked: 2
- 2018, Belbuca [Prescribing Information]
- 2018, Butrans [Prescribing Information]
Cited by
Lagisetty, P., Garpestad, C., Larkin, A., Macleod, C., Antoku, D., Slat, S., Thomas, J., Powell, V. D., Bohnert, A. S. B., & Lin, L. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108583 · Cited by 111
Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
Spreen, L. A., Dittmar, E. N., Quirk, K. C., & Smith, M. A. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2676 · Cited by 83
Buprenorphine and its formulations: a comprehensive review
Poliwoda, S., Noor, N., Jenkins, J. S., Stark, C. W., Steib, M., Hasoon, J. J., Varrassi, G., Urits, I., Viswanath, O., Kaye, A. M., et al. (2022) · Health Psychology Research · doi:10.52965/001c.37517 · Cited by 76
Pharmacological Pain Treatment in Older Persons
Pickering, G. P., Kotlińska–Lemieszek, A., Škvarč, N. K., O’Mahony, D., Monacelli, F., Knaggs, R., Morel, V., & Kocot-Kępska, M. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01151-8 · Cited by 67
Jones, K. F., Khodyakov, D., Arnold, R. M., Bulls, H. W., Dao, E., Kapo, J. M., Meier, D. E., Paice, J. A., Liebschutz, J. M., Ritchie, C., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2191 · Cited by 59
Metadata
- Authors
- Webster, L., Gudin, J., Raffa, R. B., Kuchera, J., Rauck, R., Fudin, J., Adler, J., & Mallick-Searle, T.
- Affiliations
- PRA Health Sciences (US)
- Englewood Hospital and Medical Center (US)
- University of Arizona (US)
- Cassava Sciences (United States) (US)
- Carolinas Pain Institute (US)
- Western New England University (US)
- Pacific Pain Medicine Consultants, Encinitas, California
- Division of Pain Medicine, Stanford Medicine Outpatient Center, Redwood City, California, USA
- Corresponding author
- Webster, Lynn
- Venue
- Pain Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-09
- Volume
- 21
- Issue
- 4
- Pages
- 714-723
- ISSN
- 1526-2375 (ISSN-L)
- 1526-4637
- PMC
- PMC7139205
- OpenAlex
- W2999420193
- Semantic Scholar
- cc2517b813031b59a622a7fb6090710466afcf83
- Cited by
- 130
- References
- 70
- Citations by year
- 2026: 13 · 2025: 35 · 2024: 20 · 2023: 24 · 2022: 18 · 2021: 14 · 2020: 6
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Pain Medicine (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- BioDelivery Sciences International, Inc.
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- buprenorphine, chronic pain management, opioid conversion, opioid prescribing, perioperative care, trauma management, opioid abuse potential, analgesic efficacy
- MeSH terms
- Analgesics, Opioid, Buprenorphine, Humans, Practice Guidelines as Topic, Receptors, Opioid, mu, Drug Substitution, Chronic Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. https://app.cochat.ai/papers/10.1093/pm/pnz356
- The paper
- Webster, L., Gudin, J., Raffa, R. B., Kuchera, J., Rauck, R., Fudin, J., Adler, J., & Mallick-Searle, T. (2020). Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Medicine. https://doi.org/10.1093/pm/pnz356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.